Certera Vice President and Global Head of Value and Access Oliver Leatham in a recent article published in the European Pharmaceutical Manufacturer looks at the complex issue of valuation for new drugs."How do you assign a value to saving someone’s life? Then, how do you pay the bill? Those are […]
Report Dives into FDA Regulatory Decision Making
A recent report by STAT offers a deep dive into the world of regulatory decision making inside the Food and Drug Administration (FDA) with a heavy focus on the agency's decisions on Sarepta's Exondys 51 and Vyondys 53. While the FDA gave a green light to Exondys 51 in 2016 on the condition the […]
Trump Wants Spravato for Vets
President Donald Trump during the American Veterans National Convention made clear his goal of providing veterans easy, widespread access to Johnson & Johnson's drug for treatment-resistant depression, Spravato, Endpoint News reports. Trump also called on the pharma giant to give away the drug […]
Grassley Touts Drug Pricing Bill
Republican Sen. Chuck Grassley on Thursday sought support for his key drug pricing proposal, saying that his plan would outmatch anything produced by President Donald Trump and Democrats, STAT reports. "Who knows what he's going to do at the last minute," Grassley, chairman of the Senate Finance […]
Senate Committee Green Lights Drug Pricing Bill
With unanimous support from Democrats, a Senate committee on Thursday cleared a key drug pricing bill which includes a cap on some price hikes under Medicare, STAT reports. The package was pushed through with a 19-9 vote. Five Republicans voted against the bill. To read the full report on STAT, […]
How Does Pharma Stay Strong in Washington?
A recent report by STAT looks at how the pharmaceutical industry, despite being the target of attacks from all sides, continues to keep its grip in Washington. To read the report, click here. (Paid subscription required) […]
Syneos Health Team Talks Pharma Pricing, Commercialization
Syneos Health's Value and Access team recently discussed with MM&M a range of issues impacting the pharmaceutical industry's approach to product pricing and commercialization. Pat Leary, executive vice president of clinical field teams and market access and deployment solutions, tells MM&M […]
Measure Creating Drug Pricing Board Becomes Law
A measure passed by state legislators in Maryland to create the nation's first drug affordability board became law today, July 1, according to a STAT report. The Prescription Drug Affordability Board will have the power to cap how much state and local governments pay for prescription drugs. […]
Newly-Released Emails Shed More Light into Alleged Price-Fixing Scheme
A new batch of emails made public by the Connecticut Attorney General's office this week revealed how a lawyer for Heritage Pharmaceuticals attempted to coordinate with other drugmakers for a response to a Congressional inquiry, The Middletown Press reports. "In early October 2014, Heritage […]
Article Looks at Big Pharma’s Lawsuit on TV Ad Rule
A recent article by American Council on Science and Health Senior Medical Fellow Charles Dinerstein highlights a recent lawsuit filed be three pharmaceutical companies fighting the Trump administration's mandate which requires drugmakers to include a drug's list price in television ads. Amgen, […]
